HMOs modulate immunoregulation and gut microbiota in a β-lactoglobulin-induced allergic mice model

Liu, Tingting; Chen, Peiyao; Munir, Maliha Tabassum; Liu, Libo; Li, Chun; Li, Aili; Fu, Hengfang

doi:10.1016/j.jff.2020.103993

Cited by 28 publications

(16 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, they observed a reduction in the passive response to skin anaphylaxis. Recently, Liu et al., working on a β-lactoglobulin-induced milk allergic mouse model, demonstrated that supplementation with 2’-FL for 4 weeks decreased IgE and β-lactoglobulin-specific IgE in the serum and increased the levels of the anti-inflammatory cytokines IL-10, TGF-β, and IFNγ compared to allergic mice untreated with 2’-FL, thus preventing allergy development ( 131 ).…”

Section: Hmos As a New Potential Therapeutic Agentmentioning

confidence: 99%

Human Milk Oligosaccharides: Their Effects on the Host and Their Potential as Therapeutic Agents

et al. 2021

View full text Add to dashboard Cite

Breastmilk is known to be very important for infants because it provides nutrients and immunological compounds. Among these compounds, human milk oligosaccharides (HMOs) represent the third most important component of breastmilk after lipids and lactose. Several experiments demonstrated the beneficial effects of these components on the microbiota, the immune system and epithelial barriers, which are three major biological systems. Indeed, HMOs induce bacterial colonization in the intestinal tract, which is beneficial for health. The gut bacteria can act directly and indirectly on the immune system by stimulating innate immunity and controlling inflammatory reactions and by inducing an adaptive immune response and a tolerogenic environment. In parallel, HMOs directly strengthen the intestinal epithelial barrier, protecting the host against pathogens. Here, we review the molecular mechanisms of HMOs in these different compartments and highlight their potential use as new therapeutic agents, especially in allergy prevention.

show abstract

Section: Hmos As a New Potential Therapeutic Agentmentioning

confidence: 99%

Human Milk Oligosaccharides: Their Effects on the Host and Their Potential as Therapeutic Agents

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Previous reports have confirmed a lower abundance of Lactobacillus in 𝛽-lactoglobulin-allergic mice. [49] Additionally, probiotic supplementation with Lactobacillus and Bifidobacterium species was shown to be a potential treatment for cow's milk allergy in randomized controlled trials. [50,51] Moreover, Kirjavainen et al found that taxa within Bacteroidetes were up-regulated in the GM of infants with severer milk allergy, early-onset atopic eczema, and a strong family history of allergic disorders.…”

Section: Discussionmentioning

confidence: 99%

“…Previous reports have confirmed a lower abundance of Lactobacillus in β‐lactoglobulin‐allergic mice. [ 49 ] Additionally, probiotic supplementation with Lactobacillus and Bifidobacterium species was shown to be a potential treatment for cow's milk allergy in randomized controlled trials. [ 50,51 ] Moreover, Kirjavainen et al.…”

Section: Discussionmentioning

confidence: 99%

Effects of Allergen‐Specific and Non‐Specific AGEs on the Allergenicity of Ovalbumin in a Mouse Model of Food Allergy

Zhang

et al. 2023

Molecular Nutrition Food Res

View full text Add to dashboard Cite

Scope Epidemiologic studies suggest a link between the incidence of food allergy and the consumption of dietary advanced glycation end‐products (AGEs). However, the pathogenic role of dietary AGEs in food allergy is largely unknown. This study aims to investigate the effect of allergen‐specific and non‐specific AGEs on the allergenic manifestation of ovalbumin (OVA), a typical food allergen in vivo. Methods and results OVA is glycated by methylglyoxal to prepare allergen‐specific AGEs (i.e., OVA‐AGE), and a standard AIN‐93G diet is heated to obtain allergen‐non‐specific AGEs. A BALB/c mouse model orally sensitizes to OVA with different forms of AGEs is established and the outcomes are measured as clinical signs, specific antibodies, type‐2/type‐2 cytokines, immune cell subpopulations, intestinal barrier function, and gut microbiota (GM) composition. The OVA‐AGE which has a lower immunoglobulin E (IgE)‐binding level in vitro does not reduce the allergenicity of OVA but promotes a stronger T helper 2 cells (Th2)‐response than native OVA in vivo. Both forms of AGEs up‐regulate the expression of splenic RAGE and aggravate the destruction of gut barrier and GM dysbiosis, especially when exposes to non‐relevant AGEs. Conclusion This study highlights the role of dietary AGEs in food allergy and helps to understand the biological consequences of immune‐toxic compounds in modern diet.

show abstract

“…The proportion of mice in each group was averaged and standard error of mean was calculated [28]. Besides, the anaphylactic symptoms of mice were evaluated according to the method as previously described [29]. Briefly, grading was based on the following criteria: 0-no symptoms; 1-pilar erect, scratching and rubbing around the nose and head; 2-decreased activity, puffiness around the eyes and mouth; 3-static activity time exceeds 1 min; 4-arching from the back, cyanosis around the mouth and the tail; 5-convulsion or death.…”

Section: Animal Experiments and Blg-induced Food Allergy Modelmentioning

confidence: 99%

Milk fat globule membrane supplementation protects against β-lactoglobulininduced food allergy in mice via upregulation of regulatory T cells and enhancement of intestinal barrier in a microbiota-derived short-chain fatty acids manner

Gong¹,

Li²,

Liang³

et al. 2024

Food Science and Human Wellness

View full text Add to dashboard Cite

Milk fat globule membrane (MFGM), which contains abundant glycoproteins and phospholipids, exerts beneficial effects on intestinal health and immunomodulation. The aim of this study was to evaluate the protective effects and possible underlying mechanisms of MFGM on cow's milk allergy (CMA) in a β-lactoglobulin (BLG)-induced allergic mice model. MFGM was supplemented to allergic mice induced by BLG at a dose of 400 mg/kg body weight. Results demonstrated that MFGM alleviated food allergy symptoms, decreased serum levels of lipopolysaccharide, pro-inflammatory cytokines, immunoglobulin (Ig) E, IgG1, and Th2 cytokines including interleukin (IL) -4, while increased serum levels of Th1 cytokines including interferon-γ and regulatory T cells (Tregs) cytokines including IL-10 and transforming growth factor-β. MFGM modulated gut microbiota and enhanced intestinal barrier of BLG-allergic mice, as evidenced by decreased relative abundance of Desulfobacterota, Rikenellaceae, Lachnospiraceae, and Desulfovibrionaceae, while increased relative abundance of Bacteroidetes, Lactobacillaceae and Muribaculaceae, and enhanced expressions of tight junction proteins including Occludin, Claudin-1 and zonula occludens-1. Furthermore, MFGM increased fecal short-chain fatty acids (SCFAs) levels, which elevated G protein-coupled receptor (GPR) 43 and GPR109A expressions. The increased expressions of GPR43 and GPR109A induced CD103 + dendritic cells accumulation and promoted Tregs differentiation in mesenteric lymph node to a certain extent. In summary, MFGM alleviated CMA in a BLG-induced allergic mice model through enhancing intestinal barrier and promoting Tregs differentiation, which may be correlated with SCFAs-mediated activation of GPRs. These findings suggest that MFGM may be useful as a promising functional ingredient against CMA.

show abstract

HMOs modulate immunoregulation and gut microbiota in a β-lactoglobulin-induced allergic mice model

Cited by 28 publications

References 53 publications

Human Milk Oligosaccharides: Their Effects on the Host and Their Potential as Therapeutic Agents

Human Milk Oligosaccharides: Their Effects on the Host and Their Potential as Therapeutic Agents

Effects of Allergen‐Specific and Non‐Specific AGEs on the Allergenicity of Ovalbumin in a Mouse Model of Food Allergy

Milk fat globule membrane supplementation protects against β-lactoglobulininduced food allergy in mice via upregulation of regulatory T cells and enhancement of intestinal barrier in a microbiota-derived short-chain fatty acids manner

Contact Info

Product

Resources

About